Charles Liberman - Decibel Therapeutics CoFounder Board
| DBTXDelisted Stock | USD 3.08 0.02 0.65% |
Insider
Charles Liberman is CoFounder Board of Decibel Therapeutics
| Phone | 617 370 8701 |
| Web | https://www.decibeltx.com |
Decibel Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3265) % which means that it has lost $0.3265 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7676) %, meaning that it created substantial loss on money invested by shareholders. Decibel Therapeutics' management efficiency ratios could be used to measure how well Decibel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Decibel Therapeutics currently holds 14.05 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Decibel Therapeutics has a current ratio of 6.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Decibel Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Paul MD | AN2 Therapeutics | 54 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Jc MD | Adagene | 59 | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Stewart Fisher | C4 Therapeutics | 57 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| MD MBA | Rezolute | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Randi MD | Werewolf Therapeutics | 68 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Brian Sullivan | Celcuity LLC | 62 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
Management Performance
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 |
Decibel Therapeutics Leadership Team
Elected by the shareholders, the Decibel Therapeutics' board of directors comprises two types of representatives: Decibel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Decibel. The board's role is to monitor Decibel Therapeutics' management team and ensure that shareholders' interests are well served. Decibel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Decibel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna MA, Ex Officer | ||
| Gabriel Corfas, CoFounder Board | ||
| James Murphy, Principal CFO | ||
| Charles Liberman, CoFounder Board | ||
| John Lee, Chief Officer | ||
| Joe Burns, VP Discovery | ||
| Elaine Cope, VP Operations | ||
| Ulrich Mller, CoFounder Board | ||
| Laurence Reid, CEO Pres | ||
| Albert Edge, CoFounder Board |
Decibel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Decibel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 62.95 M | |||
| Shares Outstanding | 25.13 M | |||
| Shares Owned By Insiders | 13.35 % | |||
| Shares Owned By Institutions | 61.90 % | |||
| Number Of Shares Shorted | 78.33 K | |||
| Price To Book | 0.67 X | |||
| EBITDA | (62.49 M) | |||
| Net Income | (63.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Decibel Stock
If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |